Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

Abby Jones’ first stop of the day delivering medication was the home of 90-year-old Sarah Campbell Kier. “Come in!” yelled ...

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their ...

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...

The Federal Trade Commission accused UnitedHealth's OptumRx, CVS Caremark, and Cigna's Express Scripts of pocketing over $7 ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive ...

WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...

Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...